Journal
Hemasphere
Publication Date
11-1-2023
Volume
7
Issue
11
First Page
e963
Document Type
Open Access Publication
DOI
10.1097/HS9.0000000000000963
Rights and Permissions
Kiladjian JJ, Vannucchi AM, Gerds AT, Gupta V, Verstovsek S, Egyed M, Platzbecker U, Mayer J, Grosicki S, Illés Á, Woźny T, Oh ST, McLornan D, Kirgner I, Yoon SS, Harrison CN, Klencke B, Huang M, Kawashima J, Mesa R. Momelotinib in myelofibrosis patients with thrombocytopenia: Post hoc analysis from three randomized phase 3 trials. Hemasphere. 2023 Oct 27;7(11):e963. doi: 10.1097/HS9.0000000000000963. Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access article distributed under the Creative Commons Attribution-No Derivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author
Recommended Citation
Kiladjian, Jean-Jacques; Oh, Stephen T.; and et al., "Momelotinib in myelofibrosis patients with thrombocytopenia: Post hoc analysis from three randomized phase 3 trials." Hemasphere. 7, 11. e963 (2023).
https://digitalcommons.wustl.edu/oa_4/2718
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
